SRRA | Sierra Oncology Inc. Profile | MarketWatch May 01, 2020 SRRA Sierra Oncology, Inc. Stock Quote - Stock Screener Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. Why Earnings Season Could Be Great for Sierra Oncology (SRRA) Feb 26, 2020
SRRA - Sierra Oncology Stock Price - Barchart.com Sierra Oncology (SRRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings. SRRA : 14.01 (+0.94%) Sierra Oncology to Hold Year End 2019 & 2020 Outlook Analyst & Investor Call PR Newswire - Wed Feb 26, 6:00AM CST Sierra Oncology (NASDAQ:SRRA) Lowered to Hold at Zacks ... Sierra Oncology (NASDAQ:SRRA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday, Zacks.com reports. According to Zacks, “Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and […]
Sierra Oncology Sees Hammer Chart Pattern: Time to Buy ...
Stock News - TD Ameritrade Company profile. Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology.
Sierra Oncology Inc (NASDAQ:SRRA) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating. Brokerages have set a twelve-month consensus price objective of $74.00 for the […] SRRA Split History Sierra Oncology (SRRA) has 1 split in our SRRA split history database. The split for SRRA took place on January 23, 2020. This was a 1 for 40 reverse split, meaning for each 40 shares of SRRA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 25 share position following the split.